We drive innovation in oncology and solid organ disease through development of advanced treatment and early interception We Are Alessa
Our team has significant experience in creating advanced therapeutic approaches in the lab – and transitioning them to the clinic. We came together at the UCSF Department of Hematology/Oncology, and have recruited experienced industry professionals to develop and commercialize our technology.
We are all motivated by a shared goal: to create innovative advancements in oncology and treatment of solid organ diseases.
Some 1 in 6 men will be afflicted with prostate cancer during their lifetimes. About 192,000 new cases are diagnosed each year in the U.S., and 450,000 in Europe. Nearly 30,000 men in the US die of this disease every year.
The most common invasive cancer in women, breast cancer will affect 1 in 8 women in the U.S. during their lifetimes. Each year, approximately 276,000 women are diagnosed with breast cancer.
Alessa is currently conducting their first in-man clinical study of Biolen™ PC, a minimally invasive, implantable drug delivery system for patients with localized non-metastatic prostate cancer. Biolen PC is designed to administer anti-androgen drugs to the tumor in the prostate through a sustained, localized system – without systemic exposure.
Alessa Therapeutics is a 2020 Leadership Forum and HealthTech Showcase Finalist
Alessa Therapeutics Announces First Patient Enrolled in Biolen-PC Study for Localized Drug Delivery for Prostate Cancer